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Objectives: To review clinical guidelines, recent HTA decisions, and the influ-
ence of economic analyses in HTA decisions related to biologic therapies in 
UC. MethOds: A literature review and targeted research provided information 
on clinical treatment guidelines (US and Europe) and HTAs (Europe) related to 
biologics in UC. Economic models in UC were identified and reviewed to deter-
mine how these affected HTA decisions. Results: Since several biologics were 
approved after the last version of the US treatment guidelines, the US guidelines 
only address the use of infliximab for the treatment of moderate or severe UC. 
In the UK, NICE has recommended infliximab, adalimumab, and golimumab as 
possible treatments for adults with moderate to severe UC in whom conventional 
therapy hasn’t worked or isn’t suitable. A recent NICE HTA recommends vedoli-
zumab as an option for treating moderately to severely active UC in adults only 
if the company provides vedolizumab with the discount agreed in the patient 
access scheme. The Scottish Medicines Consortium (SMC) recommends vedoli-
zumab for the treatment of adult patients with moderate-to-severe UC and an 
inadequate response, lost response, or intolerance to conventional therapy or a 
TNFα antagonist; this advice is “contingent upon the continuing availability of the 
patient access scheme in NHS Scotland or a list price that is equivalent or lower.” 
Earlier SMC advice did not recommend adalimumab, golimumab or infliximab 
for use within NHS Scotland due to lack of robust economic analyses. The SMC 
advice is superseded by the NICE HTA decisions. cOnclusiOns: In the UK and 
Scotland, more than 9 HTA have been performed in the 10 years since biologics 
have become available for the treatment of moderate-to-severe UC. Differential 
cost-effectiveness among specific indications, lines of treatment, and countries 
have resulted in a variety of recommendations as to their use which supplement 
clinical guidelines in UC.
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Objectives: The objective of this study was to describe the real-world use of 
adalimumab (ADA) for maintenance treatment of ulcerative colitis (UC) on a 
national level in Sweden. MethOds: A longitudinal, retrospective cohort study 
was conducted using the National Drug Registry and the National Patient Registry. 
UC patients (age ≥ 18 years) treated with ADA were included. Two cohorts were 
selected: (1) ADA naïve patients and (2) a cross-sectional cohort. Both cohorts were 
followed for a 12-month period. Dose escalation among the ADA naïve patients 
was defined as doubling of dose (ADA 40 mg every week) or having two follow-
ing filled prescriptions with average biweekly dose (ABD) ≥ 50 mg. Dosing in the 
cross-sectional cohort was assessed studying annual number of injections dis-
pensed among patients on maintenance treatment. Results: Five hundred and 
eighty-seven patients were identified as ADA naive during Jan 2010-April 2014. 
Dose-escalation by doubling of dose was observed in 273 (46.5%) patients with 
the median time to dose escalation being 84 days. Further analysis revealed that 
191 patients (32.5%) in the ADA naive patient cohort dose-escalated defined as 
(ABD) ≥ 50 mg, and of these 40 (20.9%) had a subsequent dose de-escalation which 
occurred after a median time of 162 days. In total 992 UC patients were identified 
in the cross-sectional cohort, defined as filling at least one prescription during May 
2013-April 2014, and of these 364 (37%) were on maintenance treatment. Out of the 
364 patients on maintenance treatment dispensing at least 22 injections during 
the period 140 (38%) received 30 injections or more. cOnclusiOns: This study 
demonstrates that UC patients receiving ADA in general have a patchy prescrip-
tion pattern, and that the proportion of patients who dose escalate is high. This 
finding and the impact that dose escalation has on costs may have implications 
for healthcare professionals and budget holders.
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Objectives: The purpose of this study is to assess the impact on physician pre-
scription behaviors of an outpatient prescription incentive program providing 
financial rewards to primary care physicians for saving prescription costs imple-
mented in October 2010 in South Korea. MethOds: A 10% sample of clinics 
(N= 1,625) was randomly selected from the entire clinics in the National Health 
Insurance claims database for the years 2009~2012, and all claims with the primary 
diagnosis of peptic ulcer or gastro-esophageal reflux diseases were extracted from 
those clinics’ data. We used a clinic-level random effects model analyzing policy 
effects on drug expenditures and prescribing behaviors including prescription rate 
of medicines treating target diseases, number of drug prescribed per claim, prescrip-
tion duration per claim. We also performed subgroup analyses by selected clinic 
characteristics, including practice type, size and specialty. Results: We found no 
significant impact of the program on drug expenditure overall. Prescription rate 
of target medicines increased and the average prescription duration per claim 
decreased after the incentive program. After the financial incentive program, clin-
ics in general medicine showed a lower prescription rate (by 0.8 percentage points), 
lower number of medicines prescribed (by 0.02), a lower prescription duration (by 
0.15 days), and lower drug expenditure per claim after the policy (by 740 won). Small 
clinics had shorter prescription duration (by 0.76 days), while large clinics and clinics 
in group practice had a higher prescription rate (by 1.5 and 2.5 percentage points, 
respectively) and higher number of medicines prescribed (by 0.03 for group practice 
only) after the program. cOnclusiOns: The financial incentive program worked as 
intended only in certain subgroup clinics for the target medicines. The reduction in 
prescription duration and the number of prescribed medicines in target claims in 
selected subgroups imply some margin for prescription adjustments.
quality of clinical evidence originating from same studies has been rated differ-
entially by different agencies. The economic evidence in this area was primarily 
based on cost-effectiveness/cost utility analysis (CEA/CUA), comprising ~95% of 
studies (time horizon 50 years to lifetime). The incremental cost-effectiveness 
ratios (ICER) ranged USD15000-200000 in PBAC, USD1246-376723 in NICE, USD750-
45200 in SMC, and USD11000-75000 in CADTH. More than 90% of the decisions 
based on ICER values were positive, with restriction being focused on cost negotia-
tions. The primary driver of positive decisions was majorly economic analysis in 
NICE, PBAC, and SMC, while clinical evidence drove positive recommendations in 
CADTH, IQWiG, and HAS. cOnclusiOns: Current landscape of CHC treatments 
in Canada, Australia, UK, Scotland, Germany, and France is majorly dominated 
by positive recommendations, considering the high unmet in this area. Most of 
the restrictions were around cost negotiations. The drivers of decisions fit with 
agency priorities, with economic analysis being the key driver in agencies with 
pharmacoeconomic analysis, and clinical evidence in agencies without pharma-
coeconomic analysis.
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Objectives: To compare the regulatory label indications and health technology 
assessment (HTA) recommendations for therapies indicated for the treatment of 
chronic hepatitis-C (CHC). MethOds: We reviewed the regulatory labels approved 
by European Medicines Agency (Europe), Health Canada (Canada) and Therapeutic 
Goods Administration (Australia). HTA reports for CHC therapies published by 
NICE (England and Wales), SMC (Scotland), HAS (France), IQWiG (Germany), CADTH 
(Canada) and PBAC (Australia) were assessed. Therapies with a positive HTA deci-
sion (recommended or restricted) were included in the analysis. Indication was 
split into four categories: age of the population (children, adults or both), fibrosis 
status (cirrhotic or non-cirrhotic), genotype, and prior treatment history (naïve or 
treatment-experienced). A match was defined as overlap of HTA and regulatory 
decision for any of the categories. Percentage correlation of the HTA indication 
with the regulatory label was calculated as the ratio of actual matches to the 
maximum possible matches for the parameters considered. Results: A total 
of 34 regulatory approvals and 48 HTA reports were identified from the public 
domain. Forty-six HTA reports providing a positive decision were included. Overall, 
HTA decisions correlated well with the marketing authorization (89%), with the 
highest correlation observed for CADTH and PBAC (100% each), followed by HAS 
(98%), NICE and SMC (86% each) and IQWiG (63%). Across agencies, highest cor-
relation was observed for age of the population (96% cases) and lowest for the 
prior treatment history (85% cases) of the population for whom the therapies were 
recommended. cOnclusiOns: Overall, the indication approved by HTA agency 
almost correlated completely with the indication granted marketing authoriza-
tion, except for NICE, SMC and IQWiG, indicating difference in agency priorities 
driving HTA decisions. Analyzing the population restriction applied by NICE, SMC 
and IQWiG would provide the decision drivers, allowing manufacturers to address 
these concerns in prospective submissions.
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Objectives: Recent advances in the management of hepatitis C virus (HCV) have 
yielded therapeutic modalities that are more efficacious, better tolerated, and have 
a lower pill and injection burden. Given the large population affected by HCV, deci-
sions by health technology assessment (HTA) bodies weigh significantly in terms 
of societal benefits and expenditures. The objective of this analysis was to evaluate 
recent patterns in HCV-related HTA decisions in selected countries. MethOds: 
HTA surveillance was conducted for Australia, Canada, France, Germany, and the 
United Kingdom (UK) from January 1, 2012 to June 1, 2015 (42 months). HTAs for 
HCV treatments were evaluated by genotype, decision, and decision rationale. 
Decisions were categorized as favorable, unfavorable, mixed (both favorable and 
unfavorable), and neutral (deferral). Results: 32 HCV-related HTAs were pub-
lished in the study time frame, with 7 assessments currently in development. 
Among the completed assessments, the majority of decisions were favorable (24, 
75%), with only 2 (6%) unfavorable and 6 (19%) mixed decisions. The most com-
mon rationales provided for a negative decision included insufficient data and/
or inappropriate comparators (4), insufficient benefit to justify the high cost (ie, 
improperly high incremental cost-effectiveness ratio [ICER]) (3), and inadequate 
clinical benefit vs the most appropriate comparator (1). France and Canada had 
the highest percentage of favorable decisions (5 of 5 and 9 of 9, respectively, 
100%), followed by the UK (3 of 4, 75%), Australia (5 of 8, 63%), and Germany (2 
of 6, 33%). cOnclusiOns: Based on the last 42 months of HCV-related HTAs, 
75% of decisions were favorable. However, the most significant factors leading to 
unfavorable assessments for HCV products are related to the inability to supply 
advantageous clinical and cost-effectiveness data. This analysis suggests that 
manufacturers would have greater success with HTA decisions if more robust 
health economic and clinical data are generated.
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